NIH Extramural Nexus (News)

On August 19, 2026, NIH released for public comment a Draft Biosafety Policy for Research Involving Biohazards for public comment. When finalized, the policy will replace the current NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules.

Research environments free from harassment, bullying, retaliation, and other hostile working conditions are fundamental to the conduct of NIH-supported biomedical studies.  These conditions enable trainees, staff, and collaborators to work effectively while preserving scientific integrity, protecting the biomedical research workforce, and ensuring the responsible stewardship of public funds. 

In June, we sought your feedback on a proposed approach to cap the number of Research Project Grants (RPG) a researcher can be principal investigator on simultaneously (NOT-OD-26-086). The proposal explored whether limits on simultaneous RPG support could contribute to a more balanced research portfolio. Here, we share some high-level outcomes from your thoughtful and helpful comments, which will inform our next steps.

We recognize it is stressful for researchers when waiting on NIH’s funding decision for submitted applications. After going through initial peer review, NIH Institute, Center, or Office (ICO) Advisory Councils review applications and make recommendations for the Institute or Center director’s consideration.

On July 28, 2026, the Administration released the U.S. Government Policy for Stopping High-Risk Life Sciences Research, pursuant to Executive Order 14292 on "Improving the Safety and Security of Biological Research.” This new government-wide policy defines areas of life sciences research that pose the greatest risk to our nation's security, implements federal funding prohibitions, and establishes a framework for addressing risk and ensuring compliance. 

NIH has a step-by-step guide available for linking an ORCID iD to an eRA Commons account.

We invite you to join a conversation between NIH leadership on NIH’s Unified Funding Strategy. Our Unified Funding Strategy is designed to support NIH Institutes and Centers to make informed, transparent, and flexible funding decisions. During their conversation, NIH leadership will clarify the approach’s rationale, goals, and implementation across NIH; address misconceptions; and help foster communication between NIH staff and research community.

A ClinicalTrials.gov study record is intended to summarize key information from a study’s protocol and the study’s findings. The study sponsor or investigator is responsible for ensuring that their studies follow all applicable laws and regulations and for submitting complete, accurate, and up-to-date information about their study.

For most career development (K) award programs, the K award recipient must commit at the minimum 9 person months, equivalent to 75% full-time professional effort, directly to their research project and career development activities. The recipient can devote the remaining effort (up to 25%) to additional research, teaching, clinical work, or other efforts complementary to their career development.

NIH supports international scientific collaboration when conducted transparently and in accordance with NIH requirements. The key expectation is timely and accurate disclosure of foreign components and related activities. Here we share reminders about how to properly acknowledge foreign components in NIH grant applications, progress reports, and manuscripts resulting from NIH awards.